afety of nemolizumab monotherapy compared with placebo in patients at least 18 years of age with moderate-to-severe prurigo nodularis over a 16- or 24-week treatment period for OLYMPIA 2 and OLYMPIA 1, respectively.

About prurigo nodularis
Prurigo nodularisis a chronic, debilitating, and distinct neuroimmune skin disease characterized by the presence of intense itch and thick skin nodules covering large body areas.10,24,25It is estimated to affect between 7-111 people per 100,000 in the European Union depending on the country.26,27The majority of patients report that the persistent itch negatively impacts their quality of life.11Furthermore, the intense itch associated with prurigo nodularis results in significant sleep disturbance and further contributes to reduced quality of life.28,29

About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio
=*=*=*=*=*=
当前为第9/16页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页